Related Experiment Video
Updated: Sep 3, 2025

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
Published on: March 12, 2013
Common Structural Pattern for Flecainide Binding in Atrial-Selective Kv1.5 and Nav1.5 Channels: A Computational
Yuliet Mazola1, José C E Márquez Montesinos1, David Ramírez2
1Center for Bioinformatics, Simulation and Modeling (CBSM), Universidad de Talca, Talca 3460000, Chile.
Researchers identified a common binding site pattern for flecainide in atrial fibrillation ion channels. This finding advances rational multi-target drug design for atrial-selective treatments.
Area of Science:
- Cardiovascular pharmacology
- Computational biophysics
- Medicinal chemistry
Background:
- Atrial fibrillation (AF) is a common arrhythmia treated with antiarrhythmic drugs (AADs) targeting cardiac ion channels.
- Current AADs face limitations including proarrhythmic effects, toxicity, and modest efficacy.
- Combined blockade of Nav1.5 and Kv1.5 channels shows potential for synergistic anti-arrhythmic effects with atrial selectivity.
Purpose of the Study:
- To investigate structural similarities in the flecainide binding site (BS) of Nav1.5 and Kv1.5 ion channels.
- To lay the groundwork for rational multi-target directed ligand (MTDL) design for atrial fibrillation.
- To identify potential targets for atrial-selective AF therapies.
Main Methods:
- Utilized a computational workflow involving docking and molecular dynamics simulations.
- Characterized the flecainide binding site in both Kv1.5 and Nav1.5 ion channel models.
- Employed pattern matching to compare structural features of the binding sites.
Main Results:
- Identified a common structural pattern within the flecainide binding site for both Nav1.5 and Kv1.5 channels.
- The common binding site pattern is located in the central cavity, featuring a hydrophobic patch and a polar region.
- Key residues involved in the binding site pattern include those from the S6 helix and P-loop.
Conclusions:
- The identified common structural pattern in flecainide binding sites provides a basis for designing novel MTDLs.
- These findings support the development of atrial-selective therapeutic strategies for AF.
- This research advances the field of rational drug design for complex cardiac arrhythmias.
More Related Videos
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Ligand-Gated Ion Channel Receptor: Gating Mechanism

